The Next Therapeutic Challenge in HIV: Polypharmacy
Edelman EJ, Gordon KS, Glover J, McNicholl IR, Fiellin DA, Justice AC. The Next Therapeutic Challenge in HIV: Polypharmacy. Drugs & Aging 2013, 30: 613-628. PMID: 23740523, PMCID: PMC3715685, DOI: 10.1007/s40266-013-0093-9.BooksConceptsAntiretroviral therapyHIV infectionSerious adverse drug eventsChronic antiretroviral therapyHarms of polypharmacyLifelong antiretroviral therapyRisk of polypharmacyCombination antiretroviral therapyNumber of medicationsAdverse drug eventsOrgan system injuryDecades of lifePhysiologic frailtyHIV patientsMore medicationsComorbid diseasesGeriatric syndromesImmune dysfunctionMedication adherenceMost HIVTherapeutic challengeChronic inflammationSystem injuryDrug eventsPolypharmacyAn internationally generalizable risk index for mortality after one year of antiretroviral therapy
Tate JP, Justice AC, Hughes MD, Bonnet F, Reiss P, Mocroft A, Nattermann J, Lampe FC, Bucher HC, Sterling TR, Crane HM, Kitahata MM, May M, Sterne JA. An internationally generalizable risk index for mortality after one year of antiretroviral therapy. AIDS 2013, 27: 563-572. PMID: 23095314, PMCID: PMC4283204, DOI: 10.1097/qad.0b013e32835b8c7f.Peer-Reviewed Original ResearchMeSH KeywordsAdultAge FactorsAgedAlanine TransaminaseAnti-HIV AgentsAspartate AminotransferasesBiomarkersCD4 Lymphocyte CountCohort StudiesEuropeFemaleHemoglobinsHepatitis CHIV InfectionsHumansMaleMiddle AgedMultiple Organ FailurePlatelet CountPredictive Value of TestsRisk AssessmentRNA, ViralUnited StatesConceptsHIV-1 RNAVeterans Aging Cohort StudyMultiorgan system injuryCD4 cell countAntiretroviral therapyVACS IndexSystem injuryCell countDetectable HIV-1 RNAART Cohort CollaborationOutcome of deathAging Cohort StudyHepatitis C statusMortality risk indexGood discriminationART initiationCohort CollaborationHCV coinfectionCohort studyHIV deathsHIV markersHIV infectionValidation cohortAlanine transaminaseExcess mortality